Daily Endocrinology Research Analysis
Three studies reshape endocrinology across mechanisms, genetics, and sex-differences. A Science paper identifies a mitonuclear stress program that de-differentiates metabolic tissues and shows pharmacologic integrated stress response blockade can restore β-cell identity. Another Science study delivers a multi-ancestry kidney “Genetic Scorecard” integrating GWAS, allele-specific expression, and single-cell multiome to prioritize causal genes and drug targets. A Nature Communications study uncover
Summary
Three studies reshape endocrinology across mechanisms, genetics, and sex-differences. A Science paper identifies a mitonuclear stress program that de-differentiates metabolic tissues and shows pharmacologic integrated stress response blockade can restore β-cell identity. Another Science study delivers a multi-ancestry kidney “Genetic Scorecard” integrating GWAS, allele-specific expression, and single-cell multiome to prioritize causal genes and drug targets. A Nature Communications study uncovers a testosterone–bone marrow axis driving post-MI neutrophilia and larger infarcts, with sex-differential response to IL-6R inhibition.
Research Themes
- Mitonuclear stress and cellular identity in metabolic tissues
- Multi-ancestry human genetics and multi-omic prioritization for kidney disease
- Sex hormones shaping immune responses and cardiovascular injury
Selected Articles
1. Retrograde mitochondrial signaling governs the identity and maturity of metabolic tissues.
Across β cells, hepatocytes, and brown adipocytes, loss of mitochondrial quality control activates a mitonuclear stress program that reduces cellular identity and maturity via the integrated stress response and chromatin remodeling. In vivo pharmacologic ISR inhibition restored β-cell identity, nominating retrograde mitochondrial signaling as a therapeutic entry point for metabolic disease.
Impact: Reveals a unifying mechanism linking mitochondrial stress to de-differentiation of key metabolic tissues and demonstrates pharmacologic reversibility. This mechanistic advance could reshape strategies for diabetes and metabolic disease by targeting ISR/retrograde signaling.
Clinical Implications: Suggests ISR modulators could preserve or restore β-cell identity and function in diabetes and potentially improve hepatic and brown adipose metabolic programs. Encourages biomarker development for mitonuclear stress states in human metabolic disease.
Key Findings
- Deficiencies in mitochondrial genome integrity, dynamics, or turnover impair oxidative phosphorylation and activate the mitochondrial integrated stress response.
- Mitonuclear signaling triggers chromatin remodeling and cellular immaturity in β cells, hepatocytes, and brown adipocytes rather than apoptosis.
- In vivo pharmacologic blockade of the integrated stress response restores β-cell identity after loss of mitochondrial quality control.
Methodological Strengths
- Cross-tissue mechanistic validation in β cells, hepatocytes, and brown adipocytes with in vivo pharmacologic rescue.
- Dissection of mitochondrial quality control components linked to ISR activation and chromatin remodeling.
Limitations
- Primarily preclinical; translational efficacy and safety of ISR blockade in humans remain untested.
- Extent to which similar mitonuclear de-differentiation occurs in human metabolic disease tissues requires confirmation.
Future Directions: Define biomarkers of mitonuclear stress in human diabetes, test ISR/mitonuclear pathway inhibitors clinically, and map chromatin remodeling targets underlying cellular immaturity.
2. Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants.
A multi-ancestry GWAS of 2.2 million individuals mapped 1026 kidney loci (97 novel) and, together with allele-specific expression and single-cell multiome data from >700 kidneys and 237,000 cells, revealed 1363 coding variants affecting 782 genes with regulatory convergence on 161 genes. Integrated into a 32-layer “Kidney Disease Genetic Scorecard,” these data prioritize causal genes, cell types, and druggable targets.
Impact: Sets a field-wide reference by unifying population-scale genetics with tissue- and cell-resolved regulatory biology and delivering a practical scorecard for target nomination.
Clinical Implications: Enables rational nomination of causal genes and drug targets in kidney disease and highlights the value of ancestry diversity for discovery and translation.
Key Findings
- Multi-ancestry GWAS (N=2.2M) identified 1026 independent kidney loci, including 97 previously unknown.
- Allele-specific expression and regulatory mapping in >700 kidneys and 237,000 cells linked 1363 coding variants to 782 genes, with regulatory convergence on 161 genes.
- Integration of 32 genetic data types yielded a Kidney Disease Genetic Scorecard prioritizing causal genes, cell types, and druggable targets; signals attenuated in European ancestry underscore discovery power of diversity.
Methodological Strengths
- Very large, multi-ancestry GWAS with tissue- and single-cell–level functional annotation.
- Comprehensive integration of 32 genetic evidence types into an actionable prioritization framework.
Limitations
- Attenuation of signals in European ancestry suggests variable power across ancestries and possible fine-mapping challenges.
- Scorecard requires external validation for clinical decision-making and prospective target qualification.
Future Directions: Prospectively validate prioritized genes and cell types, extend to underrepresented ancestries, and link scorecard predictions to therapeutic response and biomarker development.
3. Testosterone exacerbates neutrophilia and cardiac injury in myocardial infarction via actions in bone marrow.
Testosterone promotes post-MI neutrophilia and larger infarcts by suppressing CXCL12 in bone marrow stromal cells; castration or bone marrow–specific androgen receptor ablation normalizes neutrophils and improves survival. In human post-hoc analyses, men exhibited greater neutrophilia after reperfused STEMI and derived larger reductions in neutrophils and infarct size with IL-6R blockade than women.
Impact: Bridges sex hormones, bone marrow niche biology, and cardiovascular injury, providing a mechanistic basis and translational signal for sex-tailored anti-inflammatory therapy post-MI.
Clinical Implications: Supports consideration of sex-specific inflammation modulation after STEMI; suggests that men may benefit more from IL-6R blockade and highlights androgen–BM axis as a potential therapeutic target.
Key Findings
- Male mice showed higher post-MI neutrophil counts; castration reduced neutrophilia and improved survival.
- Bone marrow–specific androgen receptor ablation recapitulated the neutrophil and survival effects, implicating a BM mechanism.
- Androgens suppressed CXCL12 in BM stromal cells; in reperfused first-time STEMI patients, men had greater neutrophilia and greater reductions in neutrophils and infarct size with tocilizumab than women.
Methodological Strengths
- Convergent evidence from murine genetics, endocrine manipulation, and human post-hoc clinical analyses.
- Mechanistic link established via CXCL12 regulation in bone marrow stromal cells.
Limitations
- Human findings are post-hoc and hypothesis-generating; prospective sex-stratified trials are needed.
- Potential confounders in clinical datasets and species differences may limit direct clinical extrapolation.
Future Directions: Prospective, sex-stratified trials of IL-6R blockade post-STEMI; evaluation of androgen modulation or CXCL12-preserving strategies; biomarker development for BM-driven neutrophilia.